MedTrace Logo

Oxytocin Add-on Study for Stable Anxiety Patients

NCT00989937 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2019-09-25

Study results available
· View outcomes & findings →

Summary

The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve anxiety symptoms in patients with a variety of anxiety disorders.

Conditions

  • Anxiety Disorders

Interventions

DRUG

Oxytocin

20 IU BID or 40 IU BID

DRUG

Placebo

20 IU BID or 40 IU BID

Sponsors & Collaborators

Principal Investigators

  • David Feifel, MD, PhD · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00989937 on ClinicalTrials.gov